See the DrugPatentWatch profile for midodrine
What is midodrine’s MOA (mechanism of action)?
Midodrine is a prodrug. After you take it by mouth, your body converts it into desglymidodrine, which is the active metabolite. Desglymidodrine directly stimulates alpha-1 adrenergic (α1) receptors on blood vessels. This causes peripheral vasoconstriction, which raises vascular tone and increases blood pressure, especially in people with orthostatic hypotension.
How does that help with orthostatic hypotension?
By increasing alpha-1–mediated vasoconstriction, midodrine helps counter the drop in blood pressure that occurs when standing. That improves the ability to maintain blood pressure and reduces symptoms like dizziness or lightheadedness upon standing.
Does midodrine increase heart rate or work differently than typical alpha agonists?
The key effect described for midodrine is alpha-1 receptor stimulation leading to vasoconstriction. Whether heart rate changes in a specific patient can vary with the individual’s physiology and compensatory responses (for example, reflex mechanisms), but the primary MOA responsible for the blood pressure rise is peripheral vasoconstriction via α1 activity.
What makes midodrine different from taking an alpha-1 agonist directly?
Midodrine itself acts as a prodrug. The therapeutic effect comes after conversion to desglymidodrine, the active form that then produces alpha-1–mediated vasoconstriction.